Cargando…

2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood and Marrow Transplantation (EBMT) the number of MF has increased from 515 in 2014 to 748 in 2018 . This reflects the fac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Haris, Bacigalupo, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Annual Clinical Updates in Hematological Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293100/ https://www.ncbi.nlm.nih.gov/pubmed/34536293 http://dx.doi.org/10.1002/ajh.26349

Ejemplares similares

Hairy cell leukemia 2018: Update on diagnosis, risk‐stratification, and treatment
por: Troussard, Xavier, et al.
Publicado: (2017)

Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management
por: Hristov, Alexandra C., et al.
Publicado: (2022)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Stem cell transplantation in myelofibrosis
por: Kröger, Nicolaus
Publicado: (2018)

Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021
por: Bacigalupo, Andrea, et al.
Publicado: (2021)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
por: Zhao, Janice, et al.
Publicado: (2022)

Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants
por: Bacigalupo, Andrea
Publicado: (2022)

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
por: Jakubowiak, Andrzej J, et al.
Publicado: (2022)

High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for ‘late effects’ screening and preventive strategies
por: Samuelson, Clare, et al.
Publicado: (2016)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Frequency and Risk Factors of Cyclosporine-Induced Neurotoxicity in Allogeneic Stem Cell Transplant Recipients
por: Danish, Asma, et al.
Publicado: (2021)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B‐Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment
por: Liu, Hui, et al.
Publicado: (2018)

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
por: Liang, Winnie S., et al.
Publicado: (2018)

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation
por: Kubeczko, Marcin, et al.
Publicado: (2016)

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study
por: Wang, Hua, et al.
Publicado: (2020)

Renaissance of Radiotherapy in Intestinal Lymphoma? 10‐Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow‐up of Two German Multicenter Consecutive Prospective Phase II Trials
por: Reinartz, Gabriele, et al.
Publicado: (2020)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
por: Matasar, Matthew J., et al.
Publicado: (2019)

Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
por: Chari, Ajai, et al.
Publicado: (2019)

More Insights on the Use of γ‐Secretase Inhibitors in Cancer Treatment
por: López‐Nieva, Pilar, et al.
Publicado: (2020)

Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
por: Danilov, Alexey V, et al.
Publicado: (2022)

Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience
por: Goyal, Gaurav, et al.
Publicado: (2022)

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease
por: Martini, Dylan J, et al.
Publicado: (2022)

PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature
por: Kaplan, Henry G, et al.
Publicado: (2022)

Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life
por: Jensen, Christopher E, et al.
Publicado: (2022)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition
por: Severson, Eric A, et al.
Publicado: (2023)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
por: Muñoz, Javier, et al.
Publicado: (2023)

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study
por: Doukas, Peter G, et al.
Publicado: (2023)

Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram
por: Liu, Junqi, et al.
Publicado: (2023)

Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study
por: Musimar, Zola, et al.
Publicado: (2023)

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy
por: Burke, John M, et al.
Publicado: (2023)

Comparison of anti-thymocyte globulin-based immunosuppressive therapy and allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent non-severe aplastic anaemia: a retrospective study from a single centre
por: Shen, Yingying, et al.
Publicado: (2023)

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
por: Biavasco, Francesca, et al.
Publicado: (2022)

Incidence of acute kidney disease after receiving hematopoietic stem cell transplantation: a single-center retrospective study
por: Mima, Akira, et al.
Publicado: (2019)

The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis
por: Wolfe, Heather R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oteuq2j33poqkotncn81u6724h